Drugs / LANDOGROZUMAB
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01341470 | May 2011 → May 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01524224 | Jan 2008 → Nov 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01604408 | May 2012 → Sep 2013 | myopathy | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01505530 | Dec 2011 → Oct 2014 | malignant pancreatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01369511 | Jul 2011 → Feb 2014 | muscular atrophy | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LANDOGROZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545072 ↗ |
| Known as | Anti-myostatin antibody | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545072 ↗ |
| Known as | LY2495655 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01524224 ↗ |
| Action | Inhibit | “Anti-Myostatin Monoclonal Antibody” NCT01524224 ↗ |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody targeting myostatin” PMID 26980371 ↗ 2016 |
| Route | Intravenous | “administered intravenously or subcutaneously” NCT01341470 ↗ |
| Route | Subcutaneous | “administered intravenously or subcutaneously” NCT01341470 ↗ |
| Target | MSTN | “The humanised monoclonal antibody LY2495655 (LY) binds and neutralises myostatin.” PMID 26516121 ↗ Oct 2015 |